Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Most Down Articles

    Published in last 1 year | In last 2 years| In last 3 years| All| Most Downloaded in Recent Month | Most Downloaded in Recent Year|

    In last 2 years
    Please wait a minute...
    For Selected: Toggle Thumbnails
    Progress in clinical application of topical anesthesia
    TAO Yijia, YANG Chun, LIU Cunming
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (5): 594-600.   DOI: 10.12092/j.issn.1009-2501.2023.05.015
    Abstract192)      PDF (614KB)(611)       Save
    Topical anesthesia are being widely used in clinical diagnostic or therapeutic fields such as ophthalmology, ENT, dermatology, urology. It is defined as superficial loss of sensation in mucous membranes or skin, produced by direct application of penetrating local anesthetics. Topical anesthesia has the advantages of simple performance, high safety, quick recovery, which can effectively improve patient's satisfaction. In recent years, more and more attention has been paid to the concept of comfortable diagnosis and treatment. The new drugs and application methods of topical anesthesia are emerging constantly, special attention must be paid to their pharmacological characteristics and possible adverse reactions when using them. This article reviews the research progress of topical anesthesia in clinical application in order to provide reference for clinical practice.
    Related Articles | Metrics
    PDE4 inhibitors serve as therapeutic targets for pulmonary fibrosis 
    LIU Nanyu, YUE Hongmei, SONG Peipei, WEI Jifang, WEI Yaqian, XIE Yingying, WANG Jiaqi
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (3): 355-360.   DOI: 10.12092/j.issn.1009-2501.2023.03.015
    Abstract276)      PDF (665KB)(322)       Save
    Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal chronic interstitial lung disease characterized by a progressive decline in lung function, and current treatment options are limited. cAMP is one of the most important second messengers and plays a key role in relaxing airway smooth muscle cells and reducing inflammation. Phosphodiesterase (PDE) is a superfamily of enzymes, and PDE4 enzymes dominate 11 PDE super-family enzymes, available in four isoforms-PDE4A, PDE4B, PDE4C and PDE4D, which selectively decompose cAMP, while PDE4 inhibitors increase cAMP levels by preventing cAMP from breaking down, thereby exerting anti-inflammatory, anti-remodeling effects and providing an attractive drug target for the treatment of IPF. This review summarizes knowledge about the association of pulmonary fibrosis with PKE4, as well as emerging preclin-ical studies and clinical trials regarding PDE4 inhibitors.
    Related Articles | Metrics
    Model informed precision dosing of warfarin: China expert consensus report (2022 version)
    ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (11): 1201-1212.   DOI: 10.12092/j.issn.1009-2501.2022.11.001
    Abstract450)      PDF (780KB)(321)       Save
    Model informed precision dosing for warfarin is to provide individualized dosing by integrating information related to patient characteristics, disease status and pharmacokinetics /pharmacodynamics of warfarin, through mathematical modeling and simulation techniques based on the quantitative pharmacology. Compared with empirical dosing, it can improve the safety, effectiveness, economy, and adherence of pharmacotherapy of warfarin. This consensus report describes the commonly used modeling and simulation techniques for warfarin, their application in developing and adjusting dosing regimens, medication adherence and economy. Moreover, this consensus also elaborates the detailed procedures for the implementation in the warfarin pharmacy service pathway to facilitate the development and application of model informed precision dosing for warfarin.
    Related Articles | Metrics
    Research progress on drug treatment and drug resistance mechanism of gastrointestinal stromal tumors
    ZHAO Quanming, YANG Mandou, HU Yibo, SU Youtong, PU Li, ZHANG Yu, LI Wenliang
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (1): 82-89.   DOI: 10.12092/j.issn.1009-2501.2024.01.009
    Abstract105)      PDF (835KB)(311)       Save
    Gastrointestinal stromal tumors (GIST) are the most common mesenchymal-derived tumors of the gastrointestinal tract. Tyrosine kinase inhibitors (TKIs) are the cornerstone of GIST therapy, but mutations in resistance genes pose many problems for treatment, especially the heterogeneity of KIT resistance mutations. In recent years, with the release of a number of GIST related drug research and experimental results, the great potential of targeted therapy, immunotherapy and combination therapy to treat GIST in different directions has been revealed, providing more therapeutic directions for GIST. This article will review the experimental research and future direction in recent years.
    Related Articles | Metrics
    Mechanism of tyrosine kinase 2 inhibitors in treatment of plaque psoriasis and their progress in clinical trials 
    SHEN Jiaqing, LIU Yi
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (3): 323-330.   DOI: 10.12092/j.issn.1009-2501.2023.03.011
    Abstract188)      PDF (1286KB)(284)       Save
    As a chronic, immune-mediated in-flammatory disease, plaque psoriasis has a great burden of disease and influences on patient's physi-cal and mental health. In the past decade, plaque psoriasis treatment with biological agents achieved breakthrough development, while oral drugs with promising efficacy and safety are yet to be met. By cell signal transduction, the Janus kinase-signal transducer and activator of transcription pathway plays an important role in numerous immune-relat-ed diseases. Tyrosine kinase 2 (TYK2), a member of the JAK family, can impact on plaque psoriasis by regulating signaling and functional responses down-stream of IL-12, IL-23, IFN. Deucravacitinib, a highly selective TYK2 inhibitor, has finished its phase 3 clinical trials and shown its efficacy and safety in treatment of plaque psoriasis. Several kinds of TYK2 inhibitors are under research and develop-ment at the moment. In this review, we demon-strate roles of JAK-STAT pathway and TYK2 in plaque psoriasis as well as updates on ongoing and recently completed trials of TYK2 inhibitors. 
    Related Articles | Metrics
    Research progress on immunotherapy for triple-negative breast cancer
    HE Lihua, ZHU Xiuzhi, JIANG Yizhou
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (8): 842-853.   DOI: 10.12092/j.issn.1009-2501.2023.08.001
    Abstract403)      PDF (754KB)(283)       Save
    Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It is highly aggressive, easy to relapse, and chemotherapy remains its mainstay treatment due to the lack of therapeutic targets. In recent years, many advances have been made in the development of immunotherapy for TNBC. This review summarizes the primary modalities of immunotherapy for TNBC, including immune checkpoint inhibitors, adoptive immune cell therapy, tumor vaccines and oncolytic virus. We present the latest research progress on each treatment from the perspective of clinical study and fundamental research, while introducing the potential predictive biomarkers and resistance mechanisms of immunotherapy for TNBC.
    Related Articles | Metrics
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (9): 1077-.  
    Abstract70)      PDF (224KB)(269)       Save
    Related Articles | Metrics
    Comparison of common parameter estimation methods in NONMEM 7.5.1.: A case study of ibuprofen injection in Chinese healthy adult population 
    LUO Mingjie, LIU Runhan, ZHOU Jie, WANG Zhenlei
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (3): 290-298.   DOI: 10.12092/j.issn.1009-2501.2023.03.007
    Abstract198)      PDF (3390KB)(256)       Save
    NONMEM. is a software widely used in the field of population pharmacokinetics and pharmacodynamics, mainly for related data analy-sis. In theory, it mainly establishes a parameterized model, combines the obtained data, and uses dif-ferent parameter estimation methods to estimate the parameters in the model, and then analyzes the data according to the model. This paper briefly introduces the representation of parameterized models in NONMEM., and from statistical theory, summarizes three commonly used parameter esti-mation methods under the condition that the ran-domization effect parameters η and .do not inter-act. For nonlinear mixed effects models, the rela-tionships among three parameter estimation meth-ods are given under special cases of addictive intra-individual models and proportional intra-individual models. In addition, through numerical experi-ments on data of four pharmaceutical companies on the change of ibuprofen drug concentration with time, the rationality of theory is further veri-fied in terms of calculation time and model predic-tion residuals. 
    Related Articles | Metrics
    Progress on the pathological mechanism and treatment of frostbite 
    ZHANG Li, LIN Xingyao, SHANG Yun, WANG Qiang
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (3): 347-354.   DOI: 10.12092/j.issn.1009-2501.2023.03.014
    Abstract187)      PDF (808KB)(255)       Save
    Frostbite is a tissue injury that occurs when the body is exposed to extreme cold. Its path-ological mechanism is complex and has not been ful-ly elucidated. In high cold and high altitude areas, outdoor sports people have a high risk of injury, and severe frostbite has high disability and mortality. Ex-ploring the pathological mechanism of frostbite is helpful to determine the treatment methods and timing. At present, the clinical treatment of frostbite is mainly symptomatic treatment, such as drug treatment and surgical treatment, but the curative effect can not meet the clinical needs. Therefore, it is of great significance to seek more efficient drugs or treatment methods. This article reviews the rele-vant research progress in pathophysiological mecha-nism, clinical treatment, cellular and molecular path-ways of frostbite in recent years, in order to provide new ideas for future research and clinical treatment. 
    Related Articles | Metrics
    Molecular mechanism and treatment of pulmonary fibrosis
    ZHOU Shiqin, LUO Yali, ZHOU Wen, Qi Xiaofeng, XIAO Mengyong
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (10): 1133-1147.   DOI: 10.12092/j.issn.1009-2501.2022.10.008
    Abstract204)      PDF (2959KB)(254)       Save
    Pulmonary fibrosis (PF) is a chronic progressive interstitial lung disease. The pathogenesis of PF is not yet clear. The two anti fibrosis drugs approved for IPF treatment, nidanib and pirfenidone, have been proved to reduce the decline of pulmonary function of PF, but both have side effects. So far, there is no obvious and effective treatment to prevent the progress of PF. Therefore, this review focuses on the different cells, molecular mechanisms involved in PF and the current treatment progress of PF, so as to provide theoretical support for a better understanding of these cells, molecular mechanisms and drug development and application in PF.
    Related Articles | Metrics
    Research progress of lactate dehydrogenase A in digestive system tumors and related drugs
    WANG Siyu, LI Jiawei, LI Chenghao, LI Ling, GUO Qingyang, QIU Lu, ZHOU Shiqin, LIU Yongqi
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (4): 445-454.   DOI: 10.12092/j.issn.1009-2501.2023.04.012
    Abstract184)      PDF (1441KB)(253)       Save
    Malignant tumors of digestive system are highly prevalent malignant tumors that seriously threaten human health around the world. At present, the curative efficacy and prognosis of traditional treatment methods cannot reach the expectation, so it is urgent to find new targets for cancer treatment and realize targeted therapy for tumors. Abnormal energy metabolism in tumor  cells is regarded as a hallmark of cancer, and malignant tumor cells absorb glucose through aerobic glycolysis pathway, and obtain a small amount of energy and produce lactate under the catalysis of a series of enzymes. Lactate dehydrogenase A (Lactate dehydrogenase A, LDHA), as a key enzyme in the aerobic glycolysis pathway of tumor cells, plays an important role in the metabolic changes of tumor cells. Studies have demonstrated that LDHA has high expression characteristics in a variety of tumor cells,and its high expression in clinic is often related to the poor prognosis and high metastasis rate of tumors, which is expected to be a new target for cancer therapy. This article reviews the role of LDHA in the development of digestive system tu- mors and the research progress of related drugs.
    Related Articles | Metrics
    Application of quantitative pharmacology in vaccine research and de-velopment: overview and prospect 
    MA Guangli, ZHANG Jing
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (3): 315-322.   DOI: 10.12092/j.issn.1009-2501.2023.03.010
    Abstract190)      PDF (1748KB)(251)       Save
    This article introduces the mechanism including antigen presentation, adjuvant, lymphatic system and the characteristics of vaccine, and then summarizes the key applications of core pharmaco-metrics approaches including QSP, PK/PD, dose re-sponse analysis, MBMA, in dose-response, preclini-cal and clinical translation, and correlation be-tween biomarkers and efficacy of vaccines. It is ex-pected that the successful application of model in-formed drug development can promote model in-formed vaccine development so that pharmaco-metrics makes its due contributions to the develop-ment of safer, more effective and more controlla-ble vaccine products.
    Related Articles | Metrics
    Platelet-endothelial aggregation receptor 1 and its mediated signalling pathway Advances in the study of the role of platelets and endothelial cells
    LI Ruoning, GUO Zhanli, WANG Yuan, SUN Jianjun
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (4): 438-444.   DOI: 10.12092/j.issn.1009-2501.2023.04.011
    Abstract193)      PDF (1248KB)(246)       Save
    Platelet-aggregation  receptor 1 (PEAR1) is a transmembrane receptor identified in 2005 and expressed mainly on platelets and endothelial cells. PEAR1 is a receptor protein that contacts platelets with each other and plays an important role in platelet activation and aggregation. Endothelial cells play an important role in maintaining vascular tone and vascular repair, and PEAR1 regulates the process of tumourigenesis and development by affecting their proliferation and associated neovascularisation. In recent years, PEAR1 has gradually been recognized as a potential target for anti-thrombotic drugs. This review focuses on elucidating the mechanisms of platelet endothelial aggregation receptor 1 and related signaling pathways in platelets and endothelial cells, and provides new ideas for the study of drug therapy for tumour-associated thrombosis.
    Related Articles | Metrics
    Regulatory mechanism of LDLR and research progress of its related diseases and drugs
    LI Miao, YU Qinwei, JIANG Zhenzhou, ZHANG Luyong,
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (8): 946-954.   DOI: 10.12092/j.issn.1009-2501.2022.08.014
    Abstract445)      PDF (519KB)(238)       Save
    Cholesterol is an important lipid component in the body, which not only participates in the formation of cell membranes, but also is the raw material for the synthesis of bile acids and steroid hormones. Low density lipoprotein receptor (LDLR) is involved in cholesterol metabolism and plays an important role in maintaining the cholesterol homeostasis of organism cells. The expression of LDLR is precisely regulated by transcription, post-transcription and post-translation, and the imbalance of ldlr expression will lead to the occurrence and development of many diseases. In this paper, the molecular regulation mechanism of LDLR, the damage of target organs caused by the imbalance of LDLR expression and the research and development progress of drugs targeting LDLR are reviewed, which provides theoretical basis for further understanding of the progress of diseases related to lipid metabolism disorder and new insights for developing drugs targeting LDLR with more effective and less side effects.
    Related Articles | Metrics
    Human body networks mechanisms of melatonin and its clinical applications
    SHAO Mingkun, LIU Rong, SUN Pin, GUAN Shui, LIAO Bingcan, LI Sha, CONG Tao, LIANG Kai, MA Hui, SUN Changkai
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (9): 1031-1040.   DOI: 10.12092/j.issn.1009-2501.2022.09.010
    Abstract422)      PDF (2524KB)(234)       Save
    Melatonin is mainly an endogenous indoleamine hormone with many physiological functions. Melatonin not only plays an important role in the treatment of sleep disorders, but also plays an important role in the treatment of nervous system diseases, cancer, cardiovascular diseases, and bone diseases. In this paper, the human body networks mechanisms and the clinical applications of melatonin were summarized to provide reference for exploring the focus and direction of further clinical application research.
    Related Articles | Metrics
    New narcotic analgesics: esketamine
    JIA Tao, TENG Jinliang
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (7): 834-840.   DOI: 10.12092/j.issn.1009-2501.2022.07.015
    Abstract387)      PDF (468KB)(234)       Save
    Esketamine is an excellent anesthetic with higher potency than ketamine, fast onset of action, rapid elimination from the body, mild respiratory depression, and little impact on the circulatory system. It has unique advantages in the field of clinical anesthesia and analgesia. Its sub-anesthetic dose regimen is the most widely used in various surgeries and short examinations. Compared with traditional ketamine, the dose required for anesthesia effect and mental side effects are lower, and the analgesic effect is stronger. It has great clinical application prospects.
    Related Articles | Metrics
    General considerations for clinical pharmacology of antitumor antibody-conjugated drugs: Implications from FDA review cases
    GAO Lili, WANG Yuzhu, WANG Yan, LI Jian, WANG Jun
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (1): 75-85.   DOI: 10.12092/j.issn.1009-2501.2023.01.010
    Abstract243)      PDF (639KB)(229)       Save
    Antibody-drug conjugates (ADCs) are conjugated by a linker between an antibody drug targeting a specific antigen and a payload, such as a small cytotoxic drug. ADCs combine the potent killing effect of traditional small cytotoxic drugs with the tumor targeting property of antibody drugs. As of February 2022, the U.S. Food and Drug Administration (FDA) had approved 12 ADC anti-tumor agents. Based on the analysis of clinical pharmacology review reports of approved ADC drugs combined with relevant guidelines, it is found that in the development of ADC, in addition to the general research in clinical pharmacology, there are special considerations in dose selection and dose modification for special population due to the special anti-tumor mechanism of ADC. It is hoped that this paper will be enlightening to domestic researchers when developing ADC.
    Related Articles | Metrics
    Research progress in population pharmacokinetics of rituximab
    LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (4): 468-474.   DOI: 10.12092/j.issn.1009-2501.2023.04.015
    Abstract320)      PDF (638KB)(228)       Save
    Rituximab, a chimeric human-mouse monoclonal antibody, has been used as a first-line treatment for CD20+ B-cell non-Hodgkin lymphoma in combination with chemotherapy. It is also used for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and immunemediated nephropathy. The clinical therapeutic effect of rituximab is significant. However, individual pharmacokinetics vary greatly, which bring some uncertainties to the efficacy and safety of clinical application, individualized treatment is needed to improve the rationality of its medication. Currently, studies on the optimization of rituximab administration regimen using population pharmacokinetics have been reported. Our paper reviewed the research progress in population pharmacokinetics of rituximab, aiming to provide reference to formulate an individualized dosing scheme of rituximab and realize precise administration for domestic patients.
    Related Articles | Metrics
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (1): 116-.  
    Abstract109)      PDF (226KB)(218)       Save
    Related Articles | Metrics
    Effects of Chinese patent medicine for activating blood circulation on cardiac repair after myocardial infarction
    CHEN Xi, LI Yongjun
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (6): 680-688.   DOI: 10.12092/j.issn.1009-2501.2022.06.012
    Abstract180)      PDF (509KB)(217)       Save
    Myocardial infarction (MI) is a cardiovascular disease with high morbidity and mortality, which seriously endangers human health. Poor ways of repair after MI may damage people's life quality, therefore scientists have been committed to exploring the way of myocardial repair after MI to strive for a better prognosis of these patients. Chinese patent medicines for blood circulation activation have a long history of use in treatment of MI, where they have been shown to attenuate myocardial injury after MI and promote cardiac repair with multiple targets, links and pathways. This review focuses on a few representative Chinese patent medicines for MI and summarizes their pharmacological effects and clinical research in cardiac repair following MI, effectively providing scientific foundation on treating MI with Chinese patent medicines.
    Related Articles | Metrics
    General considerations for clinical data management of antineoplastic drugs
    MIAO Yadong, LI Xi, WANG Yan, GAO Po, ZHOU Min, YU Hao
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (9): 1055-1060.   DOI: 10.12092/j.issn.1009-2501.2022.09.013
    Abstract164)      PDF (409KB)(217)       Save
    With the enormous resources having been invested in oncology drugs development in China in recent years, the Center for Drug Evaluation (CDE) of National Medical Products Administration has been issuing a number of technical guidelines to further standardize the requirements on implementation and registration of domestic oncology clinical trials. As data is the cornerstone of clinical trials, data integrity and quality will directly decide the outcome of clinical studies. Given the specific characteristics of oncology therapeutic clinical trials, and combined with the clinical data standards established by the Clinical Data Interchange Standards Consortium (CDISC) and the issued industrial guidelines, this article introduces the general considerations of clinical data management for oncology clinical trials, with the aim of emphasizing normative data collection and timely data monitoring to ensure the data quality and reliability of results of the study. This article discusses the impact of complex study design on CRF, design CRF according to CDASH, develop DVP scientifically, rolling submissions and data cut-off.
    Related Articles | Metrics
    Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease
    ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (9): 1067-1074.   DOI: 10.12092/j.issn.1009-2501.2022.09.015
    Abstract210)      PDF (446KB)(216)       Save
    Finerenone is a new non-steroidal mineralocorticoid receptor antagonists, which can prevent and treat type 2 diabetes mellitus complicated with chronic kidney disease through antioxidant, anti-inflammatory and anti-fibrosis effects, and has a significant cardiovascular protection effect. Compared with traditional mineralocorticoid receptor antagonists, finerenone has a higher selectivity. In this review, the basic introduction, basic research, clinical research and limitations of finerenone were reviewed in order to provide more ideas and options for the treatment of type 2 diabetes mellitus complicated with chronic kidney disease.
    Related Articles | Metrics
    Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist
    ZHAO Shifeng, SONG Xiangming, YAO Jianping
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (2): 220-227.   DOI: 10.12092/j.issn.1009-2501.2023.02.014
    Abstract173)      PDF (859KB)(213)       Save
    Tirzepatide is the first-in-class dual agonist of glucagon-like peptide-1 (GLP-1) receptor  and glucose-dependent insulinotropic peptide (GIP) receptor, which plays a variety of physiological effects by imitating natural GLP-1 and GIP. In the completed large phase Ⅲ series of clinical studies of SURPASS and SURMOUNT, Tirzepatide has demonstrated excellent effects in decreasing glycosylated hemoglobin, reducing weight, improving blood lipid and other metabolic indicators, and is superior to the currently approved GLP-1 receptor agonist. Gastrointestinal reaction is the most common adverse event of the drug, which is generally mild to moderate, and decreases with continuous administration. On May 13, 2022, Tirzepatide was approved for listing by FDA, the current indication is to improve glycemic control of adult patients with type 2 diabetes (T2D) as an adjunct of diet and exercise. In addition to T2D and obesity, there are also extensive and in-depth studies on other metabolic fields. This paper makes a systematic overview of this.
    Related Articles | Metrics
    Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer
    ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (9): 1016-1030.   DOI: 10.12092/j.issn.1009-2501.2022.09.009
    Abstract204)      PDF (1935KB)(212)       Save
    Epidermal growth factor receptor (EGFR) is one of the most common targeted oncogenes in non-small cell lung cancer (NSCLC). The third-generation EGFR tyrosine kinase inhibitors (TKIs) have become the standard treatment for metastatic or recurrent NSCLC patients harboring EGFR positive or concomitant T790M mutations. However, the inevitable emergence of acquired resistance markedly limits their prolonged clinical benefits, although the third-generation EGFR TKIs have shown potent clinical outcomes in initial several months. This paper firstly reviews the characteristics and clinical efficacy of the third-generation EGFR TKIs in the market or in the clinical development. Then this article summarizes the detailed mechanisms behind the acquired drug resistance of third-generation EGFR TKIs,and further expounds the current treatment strategies to overcome the resistance. Collectively, this review could provide more information for the development and clinical application of drugs targeting EGFR.
    Related Articles | Metrics
    Exploring the intervention mechanism of Ginkgo biloba for steroid-induced necrosis of the femoral head based on network pharmacology
    CAO Fang, QIN Kairong, ZHENG Guoshuang, ZHAO Dewei
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (3): 266-275.   DOI: 10.12092/j.issn.1009-2501.2023.03.004
    Abstract168)      PDF (4588KB)(211)       Save
    AIM: To explore the mechanism of Ginkgo biloba in the treatment of steroid-induced osteonecrosis of the femoral head based on net-work pharmacology. METHODS: The active ingredients and targets of Ginkgo biloba were predicted by the TCMSP, ADME, and PharmMapper databases. The disease targets related to steroid-induced osteonecrosis of the femoral head were searched by the GeneCards and OMIM databases. Cytoscape 3.6.1 was used to construct a protein-protein inter-action network. The core target analysis, modular analysis, GO enrichment analysis, and KEGG pathway analysis of the targets of Ginkgo biloba in the intervention of steroid-induced osteonecrosis of the femoral head were performed by the STRING database. RESULTS: In this study, a total of 16 active ingredients of Ginkgo biloba and 547 targets were screened, of which 133 targets were related to steroid-induced femoral head necrosis. By PPI network topology analysis, TP53, AKT1, IL6, VEGFA, MAPK1, JUN, MAPK8, EGFR, EGF, and MYC were identified as the core targets. GO modularization analysis showed that these core targets were mainly related to apoptosis and angiogenesis. GO enrichment analysis was used to analyze the biological processes, cellular localization, and molecular functions of the core targets. KEGG enrichment analysis showed that the targets were mainly involved in molecular signaling pathways, among which the PI3K/AKT signaling pathway was the most relevant. CONCLUSION: Ginkgo biloba can inhibit steroid-induced os-teonecrosis of the femoral head through multiple components, targets, and pathways, which pro-vides the theoretical basis and reference for subse-quent cell and animal experiments.
    Related Articles | Metrics
    Design of case report form for oncology clinical trials based on CDASH
    CHEN Jianfang, LOU Donghua
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (7): 762-767.   DOI: 10.12092/j.issn.1009-2501.2022.07.006
    Abstract247)      PDF (1278KB)(208)       Save
    AIM: To investigate the design significance, method and content of the oncology clinical trial case report form (CRF) based on the clinical data acquisition standards harmonization (CDASH).  METHODS: Compared with CDASH v2.2, the characteristics of oncology clinical trial data were analyzed, and a standardized CRF was designed to meet the actual needs of oncology clinical trials. RESULTS: The CDASH was applied to the design of the CRF of the oncology clinical trial, and the data collection of the oncology clinical trial was standardized, so that the CRF design of the oncology clinical trial was relatively standardized and the data quality was improved. CONCLUSION: The implementation of oncology CRF design based on CDASH can promote the exchange and sharing of oncology clinical research data, which is conducive to improving the reliability of oncology clinical research results. 
    Related Articles | Metrics
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (3): 357-.  
    Abstract72)      PDF (227KB)(201)       Save
    Related Articles | Metrics
    Advances in the treatment of potassium-competitive acid blockers in reflux esophagitis
    YANG Mengjiao, YUAN Hao, ZHENG Ya, WANG Yuping, GUO Qinghong
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (10): 1190-1196.   DOI: 10.12092/j.issn.1009-2501.2022.10.014
    Abstract169)      PDF (771KB)(196)       Save
    Reflux Esophagitis (RE) is a gastroesophageal motility disorder mainly caused by lower esophageal sphincter disorder caused by a variety of injury factors, acid-suppressing drugs such as Proton Pump Inhibitors (PPIs) are often used clinically. With the increase of PPIs-resistant reflux esophagitis cases, the demand for the pharmacokinetics and pharmacodynamics of acid-suppressing drugs is higher. In recent years, the emergence of a new class of acid-suppressing drugs, potassium-competitive acid blockers (P-CABs), has solved some clinical deficiencies of traditional proton pump inhibitors. It has the characteristics of effective, longer-lasting acid suppression, the inhibitory effect on gastric acid secretion is not affected by the state of gastric acid secretion, the individual differences in drug metabolism and efficacy are smaller, and the drug efficacy is not affected by food intake or not. It has obvious advantages in the efficacy of severe erosive esophagitis and PPIs-resistant severe erosive esophagitis, and is more cost-effective, and is expected to replace PPI as the first-line treatment for reflux esophagitis.    
    Related Articles | Metrics
    Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study
    LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (7): 785-792.   DOI: 10.12092/j.issn.1009-2501.2022.07.009
    Abstract206)      PDF (718KB)(193)       Save
    AIM: In this study, we assessed the safety and efficacy of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack in real-world practice.  METHODS: Patients admitted for ischemic stroke/transient ischemic attack between January 1, 2018 and March 31, 2021 who continually received atorvastatin for ≥6 months after diagnosis were included. Safety and efficacy endpoints in patients receiving the generic atorvastatin were compared with those of patients receiving the branded medication. Propensity score matching was applied to control confounders. RESULTS: There were 665 patients in our final analysis, 302 in the branded group and 363 in the generic group. After propensity score matching, patients who received generic atorvastatin did not show a greater incidence of Ischemic Stroke/transient ischemic attack recurrence or onset of coronary heart disease. Similar changes in NIHSS and mRS scores were observed between the generic and branded groups. Consistent results were found in rates of hepatobiliary laboratory abnormalities and the compound adverse event profile of an elevated creatine kinase level, elevated aspartate aminotransferase/alanine aminotransferase levels, and intracranial hemorrhage. Results were consistent before and after propensity score matching. CONCLUSION: Both generic and branded atorvastatin are equally effective in preventing stroke recurrence and improving neurological deficits in patients with ischemic stroke/transient ischemic attack. Both treatments are generally well tolerated by patients.
    Related Articles | Metrics
    Research progress of ketamine psychomimetic symptoms and reward mechanism
    YANG Hang, LU Fangzhou, YANG Chun, ZHU Wei
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (12): 1347-1353.   DOI: 10.12092/j.issn.1009-2501.2022.12.004
    Abstract147)      PDF (441KB)(191)       Save
    Ketamine is a non-selective N-methyl-D-aspartic acid (NMDA) receptor antagonist. Ketamine plays a significant role in the treatment and research of neuropsychiatric diseases in recent years. The neural mechanism of ketamine psychogenic effects and reward pathway remains to be perfected, which may be closely related to a variety of neurons and pathways in the brain. This paper intends to review the relevant studies at home and abroad, and try to integrate the known neural mechanisms and put forward reasonable hypotheses.
    Related Articles | Metrics
    Research progress in plasma concentration monitoring of rivaroxaban
    YU Qiaoling, ZHAI Weiwei, LIU Ping, QIU Bo, WU Huizhen
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (7): 809-817.   DOI: 10.12092/j.issn.1009-2501.2023.07.012
    Abstract181)      PDF (654KB)(190)       Save
    Rivaroxaban, a novel oral anticoagulant drug, is widely prescribed in clinical practice. Rivaroxaban offers predictable pharmacokinetic and pharmacodynamic properties, a lowprobability of drug-drug and food-drug interactions. Compared with warfarin, rivaroxaban does not require continuous therapeutic monitoring and can be administered in fixed doses.However,in certain emergency clinical situations, such as bleeding, acute stroke, acute kidney injury, prior to urgent surgery and in the suspected accumulation of durg, plasma concentration monitoring of rivaroxaban is necessary and important for patients. Existing studies proved that there were significant individual variability and wide range in the plasma rivaroxaban concentration, which increased the risk of clinical use. Therefore, Data in the degree of rivaroxaban concentration may provide recommendations for the clinical application to promote medication safety and individuality in the future. This article collected the latest literatures and case reports related to research progress of rivaroxaban plasma concentration monitoring, and Summarized influencing factors, monitoring methods, so as to provide a basis for further study on rational use of rivaroxaban in clinical.
    Related Articles | Metrics
    Oral lienal peptides improve ammonia-induced coughing and inflammation in mice
    MAO Shuying, JIN Wei, FU Sisi, LIU Keanqi, ZHOU Zhihao, WANG Guangji, LIANG Yan
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (6): 601-607.   DOI: 10.12092/j.issn.1009-2501.2022.06.001
    Abstract298)      PDF (5468KB)(189)       Save
    AIM: To study the effect of oral lienal polypeptide on cough and inflammation in mice, in order to expand the clinical application of immune modulator lienal polypeptide and provide a new strategy for relieving cough and inflammation.  METHODS: The cough model of mice was induced by concentrated ammonia. The cough frequency and tolerance latency of mice within 6 minutes were recorded every day. The histopathological changes of spleen and lung were evaluated by HE staining and spleen index. TNF-α, IL-1β and IL-6 levels in spleen and lung of mice was detected by ELISA. RESULTS: Oral administration of spleen polypeptide could prolong the tolerance latency of mice to concentrated ammonia to a certain extent and significantly reduce the cough frequency of mice. HE staining showed that oral spleen polypeptide could significantly reduce the alveolar surface area and improve lung expansion in mice. The results of ELISA showed that oral spleen polypeptide decreased the levels of some proinflammatory factors in spleen and lung. CONCLUSION: Lienal polypeptide can alleviate cough and emphysema like symptoms induced by ammonia, improve immune ability and inflammation in mice.
    Related Articles | Metrics
    Research advance of chrysoeriol on its pharmacological action and underlying mechnism
    DENG Ying, BAI Shutong
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (10): 1155-1162.   DOI: 10.12092/j.issn.1009-2501.2022.10.010
    Abstract241)      PDF (556KB)(183)       Save
    Chrysoeriol is a natural flavonoid compound, which is widely present in many kinds of traditional Chinese medicine and medicinal herbs. In recent years, studies of Chrysoeriol on the pharmacological effects and its glycosides have gradually increased, especially in anti-tumor, anti-oxidative damage and anti-inflammatory immune regulation, etc., showing good pharmacological effects, and it has prospective potency as a candidate to develop new drug in those domain. This article briefly reviews the pharmacological effects and underlying mechanisms of chrysoeriol, so that researchers can understand the pharmacological characteristics of this compound, and also provide references for the development of new drugs based on this ingredient.
    Related Articles | Metrics
    Research progress on the treatment of autism spectrum disorders based on gut microbiota intervention
    ZHANG Qiang, ZHENG Huajun, LI Quan
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (4): 475-480.   DOI: 10.12092/j.issn.1009-2501.2023.04.016
    Abstract190)      PDF (626KB)(183)       Save
    Autism spectrum disorder is a set of neurodevelopmental disorders with unclear etiology and pathogenesis and no cure. Studies have found that the gut microbiota plays a vital role in the occurrence and development of autism spectrum disorder. By supplementing with probiotics, diet management or fecal microbial transplantation, the balance of gut microbiota can be adjusted to improve the behaviors and symptoms of patients with autism spectrum disorder. This article reviews from the perspective of regulating the bal- ance of gut microbiota to treat autism spectrum disorder, and aims to provide assistance for the re- search and treatment of autism spectrum disorder.
    Related Articles | Metrics
    State of clinical application of meloxicam
    LI Xinyu, HUANG Xin
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (2): 189-197.   DOI: 10.12092/j.issn.1009-2501.2023.02.010
    Abstract235)      PDF (603KB)(181)       Save
    Meloxicam is a long-acting non-steroidal anti-inflammatory drug, which is mainly used in the treatment of chronic osteoarthritis and postoperative analgesia. Recent studies have found that the drug has great therapeutic potential in anti-tumor, improving cognitive impairment in Alzheimer's disease, mobilizing hematopoietic stem cells and so on. This paper reviewed the pharmacological mechanism of meloxicam, the adverse reactions in gastrointestinal tract, kidney, liver and cardiovascular aspects, summarized various forms of clinical application from the perspective of preparation, and summarized the current clinical treatment strategy of combining with Western medicine and Chinese medicine respectively.
    Related Articles | Metrics
    Effect of COX-2 inhibitors on postoperative delirium in elderly patients undergoing orthopedic surgery and its possible mechanism
    WANG Jinhuo, GAO Xinyue, GUO Jianrong
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (8): 863-869.   DOI: 10.12092/j.issn.1009-2501.2022.08.004
    Abstract180)      PDF (440KB)(180)       Save
    AIM: To observe the effects of cyclooxygenase-2 (COX-2) inhibitors on the levels of inflammatory factors, nerve damage-related factors and antioxidant factors, as well as pain and delirium scores in the plasma of elderly patients with orthopaedic surgery, to clarify the role of COX-2 inhibitors in the prevention and treatment of POD and explore its possible mechanism.  METHODS: Eighty patients undergoing elective hip arthroplasty were randomly divided into parecoxib sodium group (P group, n=40) and control group (C group, n=40). Group C was injected with the same volume of normal saline at the same time point, and the preoperative cognitive function was screened 1 d (T0) before surgery by MMSE scale. The occurrence of POD was determined by CAM-CR scale score 1 d before operation (T0), 1 d after operation (T4), 3 d after operation (T6), 5 d after operation (T7). 1 d before surgery (T0), 12 h after surgery (T3), 1 d after surgery (T4), 2 d after surgery (T5). VAS scale score was used to observe the pain degree 30 min before anesthesia (T1), 1 h after surgery (T2), 1 d after surgery (T4). Central venous blood was collected from internal jugular vein 3 days after operation (T6), and the contents of inflammatory factors (IL-6 and IL-10) nerve injury related factors (S-100β protein, NSE, BDNF) and antioxidant factors (HO-1) were determined by ELISA.RESULTS: There were no significant differences in general condition, MMSE score and inflammatory factors, nerve damage-related factors and antioxidant factors between 2 groups at T1 (P>0.05). At T2 and T4, IL-6, S-100β and NSE in group P were lower than those in group C, while IL-10, BDNF and HO-1 were higher than those in group C (P<0.05). At T6, s-100 β and NSE in group P were lower than those in group C, BDNF was higher than those in group C (P<0.05), and there were no significant differences in IL-6, IL-10 and HO-1 between the two groups (P>0.05). There were no significant differences in VAS and CAM-Cr scores between the two groups at T0 (P>0.05). VAS score of group P was lower than that of group C at T3, T4 and T5 (P<0.05). At T4, T6 and T7, the CAM-CR score of P group was lower than that of C group, and the POD incidence of P group was lower than that of C group (P<0.05). CONCLUSION: COX-2 inhibitor (Parecoxib) can relieve postoperative pain in elderly patients, reduce postoperative plasma inflammatory factors and nerve injury related factors, increase antioxidant level and reduce the incidence of POD. The mechanism of POD reduction may be related to its anti-inflammatory, analgesic and antioxidant effects.
    Related Articles | Metrics
    Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice
    ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (3): 257-265.   DOI: 10.12092/j.issn.1009-2501.2023.03.003
    Abstract124)      PDF (4721KB)(180)       Save
    AIM: To investigate the effect of dapa-gliflozin on myocardial injury in type 1 diabetes mice and its mechanism. METHODS: Normal C57BL/6J male mice were randomly divided into normal control group (Control), diabetes cardiomy-opathy group (DCM) and dapagliflozin group (DA-PA). The model of diabetes was induced by strepto-zotocin (STZ) and given maintenance feed. DAPA group was given 10 mg ·kg-1·d-1 of dapagliflozin by gavage, while control group and DCM group were given 0.9% sodium chloride solution by gavage. Af-ter 8 weeks of intervention, the cardiac function of each group was measured by ultrasound; Lactate dehydrogenase (LDH) was used to detect myocardi-al injury; HE staining was used to observe the cardi-ac morphology; Masson and Sirius red staining were used to observe the degree of cardiac fibro-sis; TUNEL was used to detect myocardial apopto-sis. The expressions of NLRP3, Caspase-1, GSDMD, Collagen I, Collagen III, α-SMA, Fibronectin, Cas-pase-1 and GSDMD analyzed by immunohistochem-ical staining. The expression levels of NLRP3, Cas-pase-1, GSDMD, Collagen I, Collagen III, α-SMA, Fi-bronectin and IL-18 were detected by Western blot. RESULTS: Compared with the control group, DCM group showed abnormal echocardiographic features, increased serum lactate dehydrogenase, abnormal cardiac tissue structure, disordered ar-rangement of muscle fibers, and obvious fiber thickening and fracture. The staining intensity of apoptosis in myocardial tissue increased, the ex-pression of NLRP3, Caspase-1, GSDMD gene and protein increased, and the expression of Collagen I, Collagen III, α-SMA, fibronectin gene and protein increased. The DAPA group attenuated the previ-ously mentioned parameter changes. CONCLU-SION: Dapagliflozin can improve the degree of myo-cardial fibrosis and myocardial pyroptosis, thus im-proving the myocardial injury caused by diabetes. 
    Related Articles | Metrics
    Study on the effect of vitamin D on diabetic neuropathy through mitochondrial/autophagy pathway
    BAI Jia, YANG Hong, LI Lingling, ZHANG Yangyang, YANG Ying, LV Haihong
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (2): 214-219.   DOI: 10.12092/j.issn.1009-2501.2023.02.013
    Abstract145)      PDF (363KB)(177)       Save
    The main function of vitamin D is to regulate calcium homeostasis and bone metabolism, but in recent years, it has also been confirmed that it can participate in mitochondrial metabolism and autophagy, and further affect skeletal muscle cells, liver cells, nerve cells, etc. This article mainly discusses the effect of vitamin D on diabetic neuropathy by improving mitochondrial function and regulating autophagy, so as to provide a theoretical basis for the clinical application of vitamin D.
    Related Articles | Metrics
    Research progress of anesthesia-related neural network in depth of anesthesia monitoring
    DING Jiahui, ZHOU Yu, YUAN Tianjie, XIA Junming, LI Wenxian, HAN Yuan
    Chinese Journal of Clinical Pharmacology and Therapeutics    2022, 27 (12): 1400-1407.   DOI: 10.12092/j.issn.1009-2501.2022.12.010
    Abstract214)      PDF (513KB)(173)       Save
    Improper control of depth of anesthesia is not only detrimental to the rapid and stable recovery of anesthesia, but also affects the postoperative outcome of patients. Therefore, accurate control of anesthesia depth is an urgent clinical and scientific problem in the field of anesthesiology. At present, different algorithm models derived from electroencephalogram (EEG) signals are used to monitor the depth of anesthesia, but they cannot meet the requirements of anesthesiologists to accurately evaluate the depth of anesthesia. In recent years, the research on the mechanism and modulation of anesthesia-related neural network suggests that it has potential value as a method to monitor depth of anesthesia. Anesthesia-related neural networks mainly include sleep-wake circuit, thalamic-cortical circuit and corticocortical network. A thorough understanding of the neural network involved in the loss of consciousness caused by anesthesia will guide the depth of anesthesia monitoring more accurately and provide possibility for improving the quality of clinical anesthesia resuscitation.
    Related Articles | Metrics
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (5): 595-.  
    Abstract51)      PDF (235KB)(172)       Save
    Related Articles | Metrics